Opioid addiction is a serious problem in the United States, with approximately 2.1 million people suffering from an opioid use disorder in 2018.1 Opioid withdrawal symptoms can be debilitating and can include anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.2 Until recently, there were limited options for treating opioid withdrawal symptoms, but the approval of Lucemyra (lofexidine hydrochloride) in 2018 has revolutionized the treatment of opioid withdrawal symptoms.
Lucemyra is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the mitigation of opioid withdrawal symptoms.3 It is a selective alpha-2-adrenergic receptor agonist that works by reducing the release of norepinephrine, a neurotransmitter that is involved in the body’s response to stress.4 By blocking the release of norepinephrine, Lucemyra reduces the symptoms of opioid withdrawal.
Lucemyra is typically used in conjunction with other medications and behavioral therapies to treat opioid withdrawal symptoms. It is administered as an oral solution and is typically taken twice a day for up to 14 days.5 The dosage of Lucemyra is based on the patient’s age, weight, and severity of symptoms.6
The most significant benefit of Lucemyra is its ability to reduce the severity of opioid withdrawal symptoms.7 Studies have shown that it can reduce the severity of symptoms such as anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.8 It also has fewer side effects than other medications used to treat opioid withdrawal symptoms, such as clonidine.9 In addition to its effectiveness in treating opioid withdrawal symptoms, Lucemyra has also been shown to be effective in helping patients maintain abstinence from opioids.10 Studies have found that patients taking Lucemyra were more likely to remain abstinent from opioids for longer periods of time than those taking a placebo.11 This is an important benefit of Lucemyra, as it can help patients stay in recovery and avoid relapse.
Lucemyra is a revolutionary medication that has had a significant impact on the treatment of opioid withdrawal symptoms. It is effective in reducing the severity of symptoms and has fewer side effects than other medications used to treat opioid withdrawal. In addition, it has been shown to be effective in helping patients maintain abstinence from opioids. For these reasons, Lucemyra is an important tool in treating opioid addiction and helping patients stay in recovery.
1.
Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.
2.
Chemo causes lasting physical decline in breast cancer survivors
3.
VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets
4.
Race, Geography Linked to Gaps in Prostate Cancer Care
5.
DNA origami offers more accurate imaging in the fight against pancreatic cancer
1.
Patient Management After Personalized Surgical Oncology Reconstruction
2.
Clinical Methods in Hematology and Quality Improvement
3.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
4.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
5.
Uncovering the Hidden Symptoms of Parathyroid Cancer in Women
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding Platelet Disorders
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation